Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Corners Trial and the RESOLUTE Global Clinical Trial Program
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000006" target="_blank" >RIV/00064173:_____/16:N0000006 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/16:43912917
Result on the web
<a href="http://dx.doi.org/10.4244/EIJV12I10A199" target="_blank" >http://dx.doi.org/10.4244/EIJV12I10A199</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4244/EIJV12I10A199" target="_blank" >10.4244/EIJV12I10A199</a>
Alternative languages
Result language
angličtina
Original language name
Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Corners Trial and the RESOLUTE Global Clinical Trial Program
Original language description
Aims: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. Methods and results: We compared long-term outcomes of STEMI patients undergoing primary angio-plasty <12 hours from syniptom onset who were randomised to the R-ZES (n=122) or the everolimuseluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7.6% versus 10.4% among patients treated with R-ZES versus EES, respectively, (adjusted p=0.304), and comprised clinically driven target lesion revascularisation (TLR, 2.5% versus 2.0%, adjusted p=0.766) and cardiac death/target vessel MI (5.1% versus 9.1%, adjusted p=0.123). The five-year cumulative incidence of stent thrombosis was 0.8% for R-ZES patients versus 1.3% for EES patients (adjusted p=0.868). In the RESOLUTE Global Clinical Trial Program, excluding RESOLUTE All Comers, the three-year cumulative incidence of TLF with R-ZES was 9.8% and comprised 7.0% clinically driven TLR and 4.5% cardiac death/target vessel MI. Conclusions: Patients with STEMI who received R-ZES had excellent long-term clinical outcomes which were similar to those of patients who received EES.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EuroIntervention
ISSN
1774-024X
e-ISSN
—
Volume of the periodical
12
Issue of the periodical within the volume
10
Country of publishing house
FR - FRANCE
Number of pages
8
Pages from-to
1207-1214
UT code for WoS article
000390981500004
EID of the result in the Scopus database
2-s2.0-85001889553